Opus Genetics, Inc

Since its inception 53 years ago, the Foundation Fighting Blindness (FFB) has deployed nearly $1bn to advance treatments for inherited retinal diseases and age-related macular degeneration. Under CEO

Ocuphire Pharma Inc. and privately held Opus Genetics Inc. announced an all-stock merger on 22 October that will create a publicly traded company focused primarily on gene therapies for inherited reti

AbbVie Inc. will have direct competition for its presbyopia product Vuity, since privately held Orasis Pharmaceuticals Ltd. got US Food and Drug Administration approval for the same indication on 1

One road ahead for Ocuphire Pharma, Inc. ’s oral diabetic retinopathy drug APX3330 may have closed as it failed to meet the primary endpoint in a Phase II clinical trial, but the company is counting